Menu
"Xeno Diagnostics, LLC, was created for the purpose of improving human health by providing the necessary reagents, materials, and testing services to bridge the gap between animal models and human pathophysiology research, expanding the field of translational medicine."
One of the largest inhibitors to the advancement of translational research is a lack of specific reagents, antibodies, analytes, and support services for those scientists involved in the early stages of research and development using animal models. While great advancements have been made in the field, there is a constant need for the development of these products and services. Xeno Diagnostics’ goal is to accelerate the advancement of translational medicine by providing these often hard-to-find products and services. With an emphasis on xeno-transplantation of tissues and organs, Xeno provides products and services to researchers using Non-human Primate (NHP), Porcine, Bovine, and Human models for their research. Specifically within this area, Xeno has developed strong support services for those people and organizations in need of outsourced Mixed Lymphocyte Reactions, Cytotoxicity Assays, and other cell-based and immunological assays, which are often labor intensive.
As many of our clients are looking to move their technology through FDA approval, Xeno has adopted Good Laboratory Practices (GLP) as defined by Title 21 Code of Federal Regulations, part 58. This ensures that the research performed by Xeno Diagnostics can be done in conformance with the regulations necessary for the research to be submitted to the FDA for potential approval (please note, while GLP research originating from Xeno Diagnostics can be submitted to the FDA, this in no way guarantees that the technology will be approved). Xeno Diagnostics is also a high-complexity CLIA accredited laboratory, and is able to perform research under those regulatory requirements as well. For clients in the very early stages of discovery, Xeno can also perform assays in a Research & Development only format, in an effort to keep costs low.
Xeno Diagnostics obtained its high complexity CLIA accreditation in 2008, and through participation in the external inspection process it maintains high standards in laboratory testing. Clients also benefit from Xeno’s related organizational infrastructure including its relationships with IRB’s, patient recruitment organizations, animal product providers (body fluids, tissues, cells), and biorepositories. These collaborations have allowed Xeno to successfully handle a greater variety of projects in a shorter amount of time.
Xeno Diagnostics, LLC was established in 2007 with the purpose of providing products and services to aid in the use of pigs in transplantation and basic research. Xeno’s success in establishing ELISA, PCR, cell culture assays, and antibody development led to clients requesting assistance with other cell-based assays utilizing other animal species. To meet those needs, Xeno expanded its focus to meet those needs as well as addressing unique requests from industry, academia, and startup companies. Additional cell based assays were developed to evaluate emerging technologies ranging from implantable tissues and biosynthetic materials to test compounds aimed at treating cancers, virii, and other diseases. Currently available assays include but are not limited to: Mixed Lymphocyte Reactions (MLR’s), Cytotoxicity Assays (CDC/ADCC), Cytokine Release, Receptor Occupancy Assays, and Immunoglobulin Quantification.
Xeno Diagnostics obtained its high complexity CLIA accreditation in 2008, and through participation in the external inspection process it maintains high standards in laboratory testing. Clients also benefit from Xeno’s related organizational infrastructure including its relationships with IRB’s, patient recruitment organizations, animal product providers (body fluids, tissues, cells), and biorepositories. These collaborations have allowed Xeno to successfully handle a greater variety of projects in a shorter amount of time.
Dan Follas, MS, is CEO at Xeno Diagnostics. He received his MS from the Department of Medicinal Chemistry & Pharmacognosy, Purdue University. He worked as a Research Associate at the Indiana University Medical Center, Indianapolis, IN prior to starting Follas Laboratories in 1979 serving as President and CEO. After selling Follas Labs in 2006, Dan started Xeno Diagnostics in 2007.
Dan received his doctorate in Pharmacology & Toxicology from the University of Kansas Medical School. Prior to joining XD in 2014, his experience included teaching at the Chemical Research Institute for Toxicology and industrial experience as Research Scientist at Eli Lily in the areas of immunotoxicology and immunogenicity.
Jon began his career at XD as a laboratory technologist in 2010 after receiving his degree from Xavier University. During this time Jon also developed expertise in multiple administrative areas and assumed the position of Chief Operations Officer in 2014. Continued development in laboratory operations lead to him assuming the role of President in 2017.
Mika received her doctorate in Science and Technology from Kobe University, Japan. She worked as Lab Director/Embryologist at the Koshida Clinic, Osaka, Japan prior to taking a Postdoctoral Fellowship at the Animal Science Research Center at the University of Missouri-Columbia, Columbia, Mo. She joined Xeno Diagnostics in 2018.
Andrew received his doctorate from the Department of Chemistry at the University of Virginia in 2020. As a member of the XD scientific staff since 2020 as a Research Scientist, he has managed several client projects including custom assay development and biomaterial analysis.
After receiving her degree from Purdue University (IUPUI) in 2015, Emily worked at the Indiana State Department of Health as a Microbiologist. She joined XD in 2020 as a Laboratory Technologist performing cell-based assays, PCR, and managing cytokine analysis for several clients.
After receiving his BS in Laboratory Medicine at Far Eastern University, Manila, Philippines, Antonio received his ASCP from the North Kansas City Memorial Hospital, North Kansas City, Missouri. He worked as a Supervisor/Manager for Methodist Hospital, Covance Laboratories, and Follas Laboratories prior to joining XD in 2014.
While working as a Specialist in Department of Laboratory Medicine at Children’s Hospital, Dave earned his doctorate in clinical chemistry in the Department of Pathology at The Ohio State University. He subsequently assumed the position of Director of the Clinical Chemistry Laboratory at Nationwide Children’s Hospital in Columbus, Ohio while also assuming the position of Laboratory Director for XD in 2008.
Dick received his PhD from the University of Cincinnati in 1981 and completed post-doctoral fellowships at Vanderbilt University and Indiana University. He subsequently served as Director of Flow Cytometry at the Indiana University Health Transplant Institute. Dick has provided flow cytometry expertise to XD since 2007.
Xeno Diagnostics is proud to call itself the home of many talented and dynamic employees. We understand that our success starts with the quality of our employees. If you are interested in joining our team, feel free to submit a CV and cover letter.
Copyright © 2021. All rights reserved.
